AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10351968 — intervention group
Group type: COMPARATOR
Intervention: Patients with EF >50% (n=8)
Number of subjects: 30
Study 10351968 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with EF <50% (n=12)
Number of subjects: 30
Study 7485809 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral electrical stimulation (CES)
Number of subjects: 64
Study 7485809 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 64
Study 1743807 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 IU SMC rectally
Number of subjects: 10
Study 1743807 — intervention group
Group type: COMPARATOR
Intervention: 50 IU SMC intramuscularly
Number of subjects: 10
Study 6617596 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 0
Study 6617596 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 0
Study 6617596 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Valproate
Number of subjects: 0
Study 6617596 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 0
Study 6617596 — intervention group
Group type: EXPERIMENTAL
Intervention: Polytherapy (reduction of anticonvulsants)
Number of subjects: 0
Study 6617596 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum levels of anticonvulsants
Number of subjects: 0
Study 6617596 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy (high serum levels)
Number of subjects: 0
Study 29939243 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-visit intradermal vaccination (2 doses of 0.1 mL ID of HDCV at days 0 and 7)
Number of subjects: 500
Study 29939243 — intervention group
Group type: COMPARATOR
Intervention: 3-visit standard vaccination (single dose of 0.1 mL ID at days 0, 7, and 28)
Number of subjects: 500
Study 29939243 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 500
Study 26992719 — intervention group
Group type: EXPERIMENTAL
Intervention: Stemmed tibial component (10 mm/100 mm)
Number of subjects: 120
Study 26992719 — intervention group
Group type: COMPARATOR
Intervention: Standard cemented tibial component
Number of subjects: 120
Study 25428755 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (7.5 mg/mL)
Number of subjects: 200
Study 25428755 — intervention group
Group type: COMPARATOR
Intervention: NaCl (9 mg/mL)
Number of subjects: 200
Study 23494090 — intervention group
Group type: EXPERIMENTAL
Intervention: TCI Loop
Number of subjects: 36
Study 23494090 — intervention group
Group type: COMPARATOR
Intervention: TCI Manual
Number of subjects: 36
Study 21350038 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemplary care (EC)
Number of subjects: 0
Study 19516153 — intervention group
Group type: EXPERIMENTAL
Intervention: Q‐EGCG
Number of subjects: 39
Study 17309378 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (20 minutes of massage on five occasions)
Number of subjects: 39
Study 17309378 — intervention group
Group type: COMPARATOR
Intervention: Control group (five 20-minute visits)
Number of subjects: 39
Study 15638352 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-pump (DP) syringe change
Number of subjects: 0
Study 15638352 — intervention group
Group type: COMPARATOR
Intervention: Single-pump (SP) syringe change
Number of subjects: 0
Study 11386490 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (10-20 mg)
Number of subjects: 8
Study 11386490 — intervention group
Group type: EXPERIMENTAL
Intervention: methylphenidate (20-40 mg)
Number of subjects: 8
Study 11386490 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study 11386490 — intervention group
Group type: EXPERIMENTAL
Intervention: methylphenidate and d-amphetamine
Number of subjects: 8
Study 9595975 — intervention group
Group type: EXPERIMENTAL
Intervention: T1-weighted spin-echo MRI
Number of subjects: 5
Study 8187012 — intervention group
Group type: EXPERIMENTAL
Intervention: New pharmaceutical agents
Number of subjects: 0
Study 8187012 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic and clinical data
Number of subjects: 0
Study 8187012 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase III clinical trials
Number of subjects: 0
Study 3046283 — intervention group
Group type: EXPERIMENTAL
Intervention: APSAC (30 U as intravenous injection)
Number of subjects: 313
Study 3046283 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 313
Study 3046283 — intervention group
Group type: EXPERIMENTAL
Intervention: APSAC
Number of subjects: 313
Study 3046283 — intervention group
Group type: EXPERIMENTAL
Intervention: APSAC and Heparin
Number of subjects: 313
Study 30721549 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone therapy (GH)
Number of subjects: 60
Study 30721549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 27463698 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME)
Number of subjects: 40
Study 27463698 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 25789978 — intervention group
Group type: EXPERIMENTAL
Intervention: Jasmine rice
Number of subjects: 75
Study 25789978 — intervention group
Group type: EXPERIMENTAL
Intervention: Basmati rice
Number of subjects: 75
Study 22999815 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 104
Study 22999815 — intervention group
Group type: COMPARATOR
Intervention: Printed literature about alcohol and drug use risks (Control)
Number of subjects: 104
Study 21701341 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity focused ultrasound treatment at 59 J/cm
Number of subjects: 100
Study 21701341 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity focused ultrasound treatment at 47 J/cm
Number of subjects: 100
Study 21701341 — intervention group
Group type: COMPARATOR
Intervention: Sham control (0 J/cm)
Number of subjects: 100
Study 20175279 — intervention group
Group type: COMPARATOR
Intervention: norbactin (norfloxacin) 400 mg twice a day for 7 days
Number of subjects: 82
Study 20175279 — intervention group
Group type: EXPERIMENTAL
Intervention: furamag 50 mg 3 times a day for 10 days
Number of subjects: 82
Study 16944396 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg prednisolone (Pred)
Number of subjects: 7
Study 16944396 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg prednisolone plus 4 mg salbutamol (Pred-Sal)
Number of subjects: 7
Study 16944396 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pla)
Number of subjects: 7
Study 14996262 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental presence during emergence from anaesthesia
Number of subjects: 100
Study 14996262 — intervention group
Group type: COMPARATOR
Intervention: Control group (parent present only at induction)
Number of subjects: 100
Study 14996262 — intervention group
Group type: COMPARATOR
Intervention: Both groups (study and control)
Number of subjects: 100
Study 14996262 — intervention group
Group type: EXPERIMENTAL
Intervention: Children described as clingy/dependent
Number of subjects: 100
Study 14996262 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with frequent temper tantrums
Number of subjects: 100
Study 11334659 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial pacing
Number of subjects: 34
Study 9107384 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir (GCV)
Number of subjects: 29
Study 9107384 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet (PFA)
Number of subjects: 29
Study 7698307 — intervention group
Group type: EXPERIMENTAL
Intervention: Orion Video Home-Training Project
Number of subjects: 116
Study 7698307 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 116
Study 2966140 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin (400 mg on induction of anaesthesia and 200 mg 24 h later)
Number of subjects: 517
Study 2966140 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin (three doses of 400 mg)
Number of subjects: 517
Study 2966140 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin (80 mg tds for three days) and flucloxacillin (500 mg qds for 5 days)
Number of subjects: 517
Study 30904221 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-enriched formula (PDF)
Number of subjects: 152
Study 30904221 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard term formula (TF)
Number of subjects: 152
Study 30904221 — intervention group
Group type: COMPARATOR
Intervention: Human milk (HM)
Number of subjects: 152
Study 30254744 — intervention group
Group type: EXPERIMENTAL
Intervention: DHS5 survey questions
Number of subjects: 604
Study 30254744 — intervention group
Group type: EXPERIMENTAL
Intervention: MICS5 survey questions
Number of subjects: 604
Study 30254744 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of medicine pill boards
Number of subjects: 604
Study 27107960 — intervention group
Group type: EXPERIMENTAL
Intervention: Naprapathic manual therapy (spinal manipulation, spinal mobilization, stretching and massage)
Number of subjects: 1057
Study 27107960 — intervention group
Group type: COMPARATOR
Intervention: Naprapathic manual therapy excluding spinal manipulation
Number of subjects: 1057
Study 27107960 — intervention group
Group type: COMPARATOR
Intervention: Naprapathic manual therapy excluding stretching
Number of subjects: 1057
Study 27107960 — intervention group
Group type: EXPERIMENTAL
Intervention: Naprapathic manual therapy (all groups)
Number of subjects: 1057
Study 24812023 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise intervention
Number of subjects: 61
Study 24812023 — intervention group
Group type: COMPARATOR
Intervention: 12-week health education contact control
Number of subjects: 61
Study 22492171 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior Pelvic External Fixation (APEF)
Number of subjects: 11
Study 22492171 — intervention group
Group type: COMPARATOR
Intervention: Anterior Pelvic Internal Fixation (APIF)
Number of subjects: 11
Study 19218249 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol + Isosorbide-5-mononitrate alone (Drug)
Number of subjects: 158
Study 19218249 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol + Isosorbide-5-mononitrate combined with EBL (Drug + EBL)
Number of subjects: 158
Study 17204097 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial glycolic acid peels, topical azelaic acid 20% cream (b.i.d.), and adapalene 0.1% gel (q.i.d.)
Number of subjects: 28
Study 17204097 — intervention group
Group type: COMPARATOR
Intervention: Topical azelaic acid and adapalene (control group)
Number of subjects: 28
Study 15085092 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 20
Study 15085092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12504397 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone 12 mg/m(2) intravenously every 3 months for 24 months
Number of subjects: 194
Study 12504397 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone 12 mg/m(2)
Number of subjects: 194
Study 12504397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study 10422931 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg neostigmine in the axillary plexus and saline solution subcutaneously (group 2)
Number of subjects: 69
Study 10422931 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline solution in the axillary plexus and 500 microg neostigmine subcutaneously (group 3)
Number of subjects: 69
Study 10422931 — intervention group
Group type: COMPARATOR
Intervention: Saline solution in the axillary plexus and subcutaneously (group 1)
Number of subjects: 69
Study 7744537 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 23
Study 2399493 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly-soft (PS) X-ray film packets
Number of subjects: 25
Study 2399493 — intervention group
Group type: COMPARATOR
Intervention: Paper-pack (PP) X-ray film packets
Number of subjects: 25
Study 401005 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine (150 mg BID for 1 week, then 300 mg BID for 5 weeks)
Number of subjects: 41
Study 401005 — intervention group
Group type: COMPARATOR
Intervention: No drug (6-week no drug control condition)
Number of subjects: 41
Study 28413925 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-bead mixed amphetamine salts (MAS) 25, 50, or 75 mg
Number of subjects: 0
Study 28413925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31514391 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Community Sharp Disposal Education Module
Number of subjects: 132
Study 28101779 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical EMLA with breastfeeding (EB group)
Number of subjects: 90
Study 28101779 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapocoolant spray with breastfeeding (VB group)
Number of subjects: 90
Study 28101779 — intervention group
Group type: COMPARATOR
Intervention: Only breastfeeding (BO group)
Number of subjects: 90
Study 26481581 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention delivered by a case manager in the primary care setting
Number of subjects: 33
Study 25136638 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 tablets (2.4 gr/day)
Number of subjects: 90
Study 25136638 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E tablets (400 IU/day)
Number of subjects: 90
Study 25136638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 22524471 — intervention group
Group type: EXPERIMENTAL
Intervention: Parotid gland massage
Number of subjects: 60
Study 22524471 — intervention group
Group type: COMPARATOR
Intervention: No massage (Control)
Number of subjects: 60
Study 19348541 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing very cute images (puppies and kittens)
Number of subjects: 2
Study 19348541 — intervention group
Group type: COMPARATOR
Intervention: Viewing slightly cute images (dogs and cats)
Number of subjects: 2
Study 17068486 — intervention group
Group type: EXPERIMENTAL
Intervention: Free SCs intervention (FS)
Number of subjects: 364
Study 17068486 — intervention group
Group type: EXPERIMENTAL
Intervention: Same free SCs with explicit labeling (FNL)
Number of subjects: 364
Study 17068486 — intervention group
Group type: COMPARATOR
Intervention: No intervention (NI)
Number of subjects: 364
Study 15338687 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous calcitriol therapy (Group III)
Number of subjects: 24
Study 15338687 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcitriol therapy (Group II)
Number of subjects: 24
Study 15338687 — intervention group
Group type: COMPARATOR
Intervention: No calcitriol therapy (Group I)
Number of subjects: 24
Study 11229829 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic oil (GO) capsules, 12.3 mg/day for 16 weeks
Number of subjects: 27
Study 9594353 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic hypoxia at high altitude (5,050 m) for thirty-four days
Number of subjects: 9
Study 9594353 — intervention group
Group type: COMPARATOR
Intervention: Sea level
Number of subjects: 9
Study 7735929 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with clarithromycin (200 mg, three times a day) + sofalcone (100 mg, three times a day) for 3 weeks
Number of subjects: 42
Study 7735929 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy with clarithromycin (200 mg, three times a day) + sofalcone (100 mg, three times a day) for 2 weeks
Number of subjects: 42
Study 7735929 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with clarithromycin + sofalcone
Number of subjects: 42
Study 1976379 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 40 mg
Number of subjects: 86
Study 1976379 — intervention group
Group type: COMPARATOR
Intervention: Pseudoephedrine 60 mg
Number of subjects: 86
Study 1976379 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of terfenadine 40 mg and pseudoephedrine 60 mg
Number of subjects: 86
Study 380580 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of diazepam
Number of subjects: 149
Study 380580 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg of Bay g 5653
Number of subjects: 149
Study 380580 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of Bay g 5653
Number of subjects: 149
Study 380580 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of Bay g 5653
Number of subjects: 149
Study 380580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 31089108 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaly device stimulation of the supraorbital nerve
Number of subjects: 0
Study 31089108 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 28059806 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 Hz transcranial alternating current stimulation (tACS) for frontoparietal network desynchronization
Number of subjects: 0
Study 28059806 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 26096765 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD6482 + aspirin
Number of subjects: 0
Study 26096765 — intervention group
Group type: EXPERIMENTAL
Intervention: PI3Kβ inhibition
Number of subjects: 0
Study 26096765 — intervention group
Group type: EXPERIMENTAL
Intervention: P2Y12 + PI3Kβ
Number of subjects: 0
Study 26096765 — intervention group
Group type: EXPERIMENTAL
Intervention: P2Y12 + COX‐1
Number of subjects: 0
Study 26096765 — intervention group
Group type: EXPERIMENTAL
Intervention: PI3Kβ + COX‐1
Number of subjects: 0
Study 26096765 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (P2Y12 + PI3Kβ + COX‐1)
Number of subjects: 0
Study 26096765 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD6482
Number of subjects: 0
Study 26096765 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel + aspirin
Number of subjects: 0
Study 23497759 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally disintegrating film (ODF) formulation of sildenafil, 50 mg (part 1)
Number of subjects: 120
Study 23497759 — intervention group
Group type: COMPARATOR
Intervention: Film-coated tablet (FCT) formulation of sildenafil, 50 mg (part 1)
Number of subjects: 120
Study 23497759 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally disintegrating film (ODF) formulation of sildenafil, 100 mg (part 2)
Number of subjects: 120
Study 23497759 — intervention group
Group type: COMPARATOR
Intervention: Film-coated tablet (FCT) formulation of sildenafil, 100 mg (part 2)
Number of subjects: 120
Study 23497759 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (AEs) with ODF and FCT formulations
Number of subjects: 120
Study 21692601 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (90 mg twice daily)
Number of subjects: 22
Study 21692601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 19622998 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Number of subjects: 2
Study 18090169 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (1200 mg every 12 hrs, starting immediately before cardiac surgery)
Number of subjects: 254
Study 18090169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 18090169 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 254
Study 15200747 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (CT) with nateglinide (120 mg, ac) and metformin (500 mg, tid)
Number of subjects: 401
Study 15200747 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (CT)
Number of subjects: 401
Study 15200747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study 11115582 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with TAI of 120 mg/body cisplatin twice a month at 4-week intervals
Number of subjects: 60
Study 11115582 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy with 200 mg/day oral 5‐FU or UFT every day
Number of subjects: 60
Study 11115582 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival and disease-free survival rates
Number of subjects: 60
Study 9600369 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen, 40 mg/day
Number of subjects: 80
Study 9600369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 7993983 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg)
Number of subjects: 12
Study 7993983 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril (20 mg)
Number of subjects: 12
Study 7993983 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of aspirin and benazepril
Number of subjects: 12
Study 2730972 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory stimulation protocol
Number of subjects: 45
Study 7002 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.5 mg)
Number of subjects: 30
Study 7002 — intervention group
Group type: COMPARATOR
Intervention: Methyprylon
Number of subjects: 30
Study 11380131 — intervention group
Group type: EXPERIMENTAL
Intervention: Home management (short-arm backslab removed at home after three weeks)
Number of subjects: 87
Study 11380131 — intervention group
Group type: COMPARATOR
Intervention: Hospital management (normal practice, attended fracture clinic after three weeks)
Number of subjects: 87
Study 11380131 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups' preference for backslab removal
Number of subjects: 87
Study 31669225 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive inhalation of hypertonic saline
Number of subjects: 0
Study 26334244 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 40
Study 26334244 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline solution)
Number of subjects: 40
Study 26272857 — intervention group
Group type: EXPERIMENTAL
Intervention: In-classroom training by an endoscopist with expertise in NBI
Number of subjects: 33
Study 26272857 — intervention group
Group type: COMPARATOR
Intervention: Self-directed training with an automated version of the presentation
Number of subjects: 33
Study 25256893 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green retention rate at 15 minutes (ICGR15)
Number of subjects: 878
Study 25256893 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour site
Number of subjects: 878
Study 25256893 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 878